In the latest round up of Houston innovation news you may have missed, local venture groups announce new investments, Houston schools launch programs, and more. Photo via UH.edu

It's been a horrific week for both the city of Houston and the state of Texas. Millions of residents have lost power and/or water due to a winter storm that brought low temps. For this reason, Houston innovation news may have fallen through some of the cracks.

In this roundup of short stories within Houston innovation, the Texas Medical Center's Venture Fund and Chevron Technology Ventures make new investments, University of Houston professors make big moves, both Rice University and UH announce new programs, and more.

TMCx company raises $2 million

The Texas Medical Center Venture Fund announced its latest investment. Noninvasix Inc., a startup working on novel precision oximetry technology announced it has closed an over-subscribed seed round at $2 million led by the TMC Venture Fund with support from Philips and GPG Ventures. The funds will help the company advance product development and attain FDA clearance.

"TMC Venture Fund has been a strong supporter of Noninvasix since our initial investment in the company, and we look forward to our continued partnership with them," says Tom Luby, director of TMC Innovation, in a news release. "The potential of this platform technology to guide better clinical decision-making and improve outcomes has us excited to be part of the effort that brings the optoacoustic technology to the market."

The Noninvasix team has created a solution for the safe, accurate and non-invasive monitoring of infant welfare in the neonatal intensive care unit.

"Brain hypoxia, characterized by restricted blood flow to the brain, accounts for 23 percent of all neonatal deaths worldwide and costs the U.S. healthcare system over $7 billion per year, making the development of an accurate and precise patient monitoring system a top maternal-fetal health priority," says Noninvasix CEO Graham Randall, in the release.

"Noninvasix's novel solution utilizes optoacoustic monitoring of cerebral venous oxygenation to accurately measure the adequacy of the oxygen supply to a baby's brain in real time."

The Cannon and the University of Houston launch new partnership

A UH program has teamed up with a local startup development organization. Photo courtesy of The Cannon

The Cannon has partnered up with the Wolff Center for Entrepreneurship at the University of Houston to launch a semester-long program that will introduce students to the Startup Development Organization Network.Through the new collaboration, students will have access to new opportunities to interact and connect with professionals and advisers.

"We couldn't be prouder to partner with the University of Houston and the Wolff Center for Entrepreneurship to engage with the students that will soon be driving innovation in Houston and beyond," says Jon Lambert, CEO of The Cannon, in a news release. "UH is widely recognized for its excellence in entrepreneurial education and what Dave Cook and his team have built through The Wolff Center is second to none.

"The Cannon is excited for the opportunity to play a role in enhancing the entrepreneurial education journey through helping to provide a bridge between world-class academic programming and the commercial entrepreneurial landscape."

Students at WCE will receive access to The Cannon's online platform, Cannon Connect, as well as access to exclusive events hosted by The Cannon.

Rice University launches new data science program

Rice University is now offering a master's in data science beginning in the fall. Photo courtesy of Rice

Rice University has announced it's creating a Master of Data Science program. The degree is offered through the George R. Brown School of Engineering and managed by the Department of Computer Science. With classes beginning in the fall, applications are now open.

"The field of data science touches almost every industry in our economy," says Scott Rixner, a professor in the Rice's Department of Computer Science, in a press release. "This degree will provide those seeking to find new careers, or to advance in their current careers, the opportunity to acquire an indispensable skill set and to build future-focused critical expertise that will drive future innovation."

The 31-credit program will be offer classes both online and face-to-face, according to the release. The courses will deliver the skills needed to collect, evaluate, interpret and present data for effective decision-making across a variety of industries. The new program joins the online Master of Computer Science degree that was launched in 2019.

"Data science has revolutionized all fields of study and many sectors of the industry where data is central to the scientific or industrial endeavor," says Rice Dean of Engineering Luay Nakhleh, in the release. "Data-driven discovery has complemented hypothesis-driven discovery, and it is here to stay. This degree positions our students for rewarding, life-long careers that provide meaningful impact in design and research in a multitude of industries."

Houston biotech company with COVID-19 treatment enters agreement with UH

A UH-founded biotech company has a new partnership to announce. Image via Getty Images

AuraVax Therapeutics Inc. has entered into an exclusive license agreement with the University of Houston for its intranasal vaccine and therapeutics technology platform. The biotech company is developing novel intranasal vaccines and therapies to help patients defeat debilitating diseases including COVID-19. This new agreement upgrades the optioned intellectual property between UH and AuraVax announced in October.

The vaccine is a nasal inhalant, similar to FluMist, and was developed by Navin Varadarajan, an M.D. Anderson professor of chemical and biomolecular engineering at UH. Varadarajan is a co-founder of AuraVax.

"We are excited to rapidly expand our relationship with the University of Houston to advance the development of this novel intranasal approach to tackle respiratory viruses. We plan to stop COVID-19 at its point of entry — the nasal cavity — and we believe our intranasal platform represents a differentiated solution that will lead to a vaccine to create sustained immunity to COVID-19 and other viruses," says Varadarajan, in the news release.

Chevron Technology Ventures makes latest investment

CTV has recently invested in a geothermal energy company. Photo via eavor.com

Houston-based Chevron Technology Ventures has announced its latest investment in Eavor Technologies Inc., a Canadian company that closed a $40 million funding round. Eavor is working on a scalable geothermal technology and hopes to power the equivalent of 10 million homes by 2030.

Eavor-Loop™, Eavor's technology, uses the natural heat of the earth like a battery and is different from what's on the market because of its scalable and transportatable application — as well as because it produces zero emissions.

Along with CTV, investors included bp Ventures, Temasek, BDC Capital, Eversource1, and Vickers Venture Partners.

"I am delighted that with the funding closed in this round we can look forward to bringing down the cost of clean, dispatchable power to a universally competitive level – an important milestone for renewable energy," says John Redfern, president and CEO of the company, in a news release. "The involvement of companies such as bp and Chevron represents a fantastic endorsement of our technology, the progress we have made to date and the promise for its global scalability."

3 UH engineers named to Academy of Inventors

Three UH engineers have been named senior members of the National Academy of Inventors. Photos via UH.edu

The National Academy of Inventors have named three University of Houston Cullen College of Engineering researchers senior members for 2021.

Hien Nguyen, assistant professor of electrical and computer engineering; Jeffrey Rimer, Abraham E. Dukler Endowed Chair, William A. Brookshire Department of Chemical and Biomolecular Engineering; and Gangbing Song, Moores Professor of Mechanical Engineering, are among the 61 selected for the distinguishment, according to a press release from UH.

"This national distinction honoring the research and scholarship of Drs. Nguyen, Rimer and Song is emblematic of the reputation for innovation fostered at the Cullen College of Engineering," says Paula Myrick Short, senior vice president for academic affairs and provost at UH, in the release. "I congratulate these three outstanding faculty members for this well-deserved recognition."

Nguyen works with biomedical data analysis and artificial intelligence, Rimer's expertise in the processes behind crystal growth and formation, and Song researches the development of actuator systems for aerospace, biomedical and oil exploration applications.

A full list of NAI Senior Members is available on the NAI website.

Aziz Gilani to be recognized nationally

A Houston investor is being recognized nationally. Photo va mercuryfund.com

Aziz Gilani, managing director at Houston-based Mercury Fund, was just selected for an award from the National Venture Capital Association. Gilani is being recognized with the Outstanding Service Award for his work last year outlining and explaining the Paycheck Protection Program from the Small Business Administration to entrepreneurs.

The award will be presented at NVCA's virtual ceremony on March 9. More info on the award ceremony here.

UH and a local company are developing a new COVID-19 vaccine. Photo by Getty Images

University of Houston partners with local company to develop cutting-edge COVID vaccine

COOGS TACKLE COVID

A major Houston university has taken a big leap in the race to battle debilitating diseases such as COVID-19. The University of Houston has entered into an exclusive license option agreement with AuraVax Therapeutics Inc., a Houston-based biotech company developing novel vaccines against aggressive respiratory diseases such as coronavirus, according to a press release.

This means AuraVax has the option to exclusively license a new intranasal COVID-19 vaccine technology developed by Navin Varadarajan, an M.D. Anderson professor of chemical and biomolecular engineering. Varadarajan is a co-founder of AuraVax.

The vaccine is a nasal inhalant, much like FluMist. Based on pre-clinical experimentation, Varadarajan reports his technology not only elicits a mucosal immune response, but also systemic immunity, according to UH.

"We plan to stop COVID-19, a respiratory virus, at its point of entry — the nasal cavity — and we believe our intranasal platform is a differentiated approach that will lead to a vaccine with increased efficacy to create sustained immunity to COVID-19," said Varadarajan in a statement.

So how does it work? Varadarajan is utilizing the spike protein, which helps the virus enter the target cell, and is the major target for neutralizing antibodies as it binds to the ACE 2 cellular receptor, for virus entry. The professor prefers using proteins because of their ability to induce strong immune responses, flexibility and scalability, and the absence of infectious particles, per UH.

Varadarajan's company, AuraVax, has created a next-generation vaccine platform that combines the potential of in-home administration with the ability to deliver complete immunity. The technology has been validated for COVID-19 in initial animal studies and results in immunity measured by both B-cell and T-cell responses.

"We believe AuraVax has a competitive advantage given the immune responses and a supply chain that is well-suited for widespread distribution and self-administration distribution," said Varadarajan. "We are excited to be collaborating with the University of Houston and look forward to future success by advancing the development of this novel intranasal vaccine technology to address a multitude of respiratory viruses, starting with COVID-19."

------

This article originally ran on CultureMap.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Houston geothermal unicorn Fervo officially files for IPO

going public

Fervo Energy has officially filed for IPO.

The Houston-based geothermal unicorn filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission on April 17 to list its Class A common stock on the Nasdaq exchange. Fervo intends to be listed under the ticker symbol "FRVO."

The number and price of the shares have not yet been determined, according to a news release from Fervo. J.P. Morgan, BofA Securities, RBC Capital Markets and Barclays are leading the offering.

The highly anticipated filing comes as Fervo readies its flagship Cape Station geothermal project to deliver its first power later this year

"Today, miles-long lines for gasoline have been replaced by lines for electricity. Tech companies compete for megawatts to claim AI market share. Manufacturers jockey for power to strengthen American industry. Utilities demand clean, firm electricity to stabilize the grid," Fervo CEO Tim Latimer shared in the filing. "Fervo is prepared to serve all of these customers. Not with complex, idiosyncratic projects but with a simplified, standardized product capable of delivering around-the-clock, carbon-free power using proven oil and gas technology."

Fervo has been preparing to file for IPO for months. Axios Pro first reported that the company "quietly" filed for an IPO in January and estimated it would be valued between $2 billion and $3 billion.

Fervo also closed $421 million in non-recourse debt financing for the first phase of Cape Station last month and raised a $462 million Series E in December. The company also announced the addition of four heavyweights to its board of directors last week, including Meg Whitman, former CEO of eBay, Hewlett-Packard, and Spring-based HPE.

Fervo reported a net loss of $70.5 million for the 2025 fiscal year in the S-1 filing and a loss of $41.1 million in 2024.

Tracxn.com estimates that Fervo has raised $1.12 billion over 12 funding rounds. The company was founded in 2017 by Latimer and CTO Jack Norbeck.

---

This article originally appeared on our sister site, EnergyCapitalHTX.com.

New UT Austin med center, anchored by MD Anderson, gets $1 billion gift

Future of Health

A donation announced Tuesday, April 21, breaks a major record at the University of Texas at Austin. Michael and Susan Dell are now UT Austin's first supporters to give $1 billion. In response, the university will create the UT Dell Campus for Advanced Research and the UT Dell Medical Center to "advance human health," per a press release.

The release also records "significant support" for undergraduate scholarships, student housing, and the Texas Advanced Computing Center for supercomputing research.

Both the new research campus and the UT Dell Medical Center will integrate advanced computing into their research and practices. At the medical center, the university hopes that will lead to "earlier detection, more precise and personalized care, and better health outcomes." The University of Texas MD Anderson Cancer Center will also be integrated into the new medical center.

That comes with a numeric goal measured in 10s: raise $10 billion and rank among the top 10 medical centers in the U.S., both in the next decade.

In the shorter term, the university will break ground on the medical center with architecture firm Skidmore, Owings & Merrill (SOM) "later this year."

“UT Austin, where Dell Technologies was founded from a dorm room, has always been a place where bold ideas become real-world impact,” said Michael and Susan Dell in a joint statement.

They continued, “What makes this moment so meaningful is the opportunity to build something that brings every part of the journey together — from how students learn, to how discoveries are made, to how care reaches families. By bringing together medicine, science and computing in one campus designed for the AI era, UT can create more opportunity, deliver better outcomes, and build a stronger future for communities across Texas and beyond.”

This is the second major gift this year for the planned multibillion-dollar medical center. In January, Tench Coxe, a former venture capitalist who’s a major shareholder in chipmaking giant Nvidia, and Simone Coxe, co-founder and former CEO of the Blanc & Otus PR firm, contributed $100 million$100 million.

Baylor scientist lands $2M grant to explore links between viruses and Alzheimer’s

Alzheimer’s research

A Baylor College of Medicine scientist will begin exploring the possible link between Alzheimer’s disease and viral infections thanks to a $2 million grant awarded in March.

Dr. Ryan S. Dhindsa is an assistant professor of pathology & immunology at Baylor and a principal investigator at Texas Children’s Duncan Neurological Research Institute (Duncan NRI). He hypothesizes that Alzheimer’s may have some link to previous viral infections contracted by the patient. To study this intriguing possibility, the American Brain Foundation has gifted him the Cure One, Cure Many award in neuroinflammation.

“It is an honor to receive this support from the Cure One, Cure Many Award. Viral infections are emerging as a major, underappreciated driver of Alzheimer's disease, and this award will allow our team to conduct the most comprehensive screen of viral exposures and host genetics in Alzheimer's to date, spanning over a million individuals,” Dhindsa said in a news release. “Our goal is to identify which viruses matter most, why some people are more vulnerable than others, and ultimately move the field closer to new therapeutic strategies for patients.”

Roughly 150 million people worldwide will suffer from Alzheimer’s by 2050, making it the most common cause of dementia in the world. Despite this, scientists are still at a loss as to what exactly causes it.

Dhindsa’s research is part of a new range of theories that certain viral infections may trigger Alzheimer’s. His team will take a two-fold approach. First, they will analyze the medical records of more than a million individuals looking for patterns. Second, they will analyze viral DNA in stem cell-derived brain cells to see how the infections could contribute to neurological decay. The scale of the genomic data gathering is unprecedented and may highlight a link that traditional studies have missed.

Also joining the project are Dr. Caleb Lareau of Memorial Sloan Kettering Cancer Center and Dr. Artem Babaian of the University of Toronto. Should a link be found, it would open the door to using anti-virals to prevent or treat Alzheimer’s.